Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Genomic determinants of treatment outcome and identification of a new genomic subset of adult acute lymphoblastic leukemia from the ECOG-ACRIN E1910 randomized phase III trial

View Full Paper
Ask AI
Bookmark
Share

Authors

LMLindsey E. MontefioriZSZhuoxin SunTCTi‐Cheng Chang

Discussion

Loading...

Member takes

Overview

Analysis identifies genomic markers correlating with MRD negativity in adult acute lymphoblastic leukemia, indicating blinatumomab may enhance treatment response.

Key Points

  • Blinatumomab improved relapse-free survival in specific molecular subgroups of adult acute lymphoblastic leukemia.
  • Analysis of 569 adults revealed a novel group characterized by CEBPA deregulation and genomic alterations.
  • Whole genome sequencing and whole exome sequencing revealed critical epigenetic regulation pathways in B-ALL.
  • Adult acute lymphoblastic leukemia treatment outcomes correlate with specific genomic determinants, emphasizing precision medicine.

Cite This Study

Montefiori et al. (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e5ebhttps://doi.org/10.1182/blood-2025-31
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinical value of advanced genomic testing in adult Philadelphia-negative B-ALL: Results from the CZ national leukemia study group (CELL)2025
  2. 2Blinatumomab efficacy differs between newly diagnosed and relapsed/refractory B-ALL: Impact on MRD clearance and survival2025
  3. 3Low-intensity cytoreduction with low-dose cytarabine prior to blinatumomab for pediatric and AYA R/R ALL integrated with multi-omics analysis to discover predictive biomarkers: Initial results from JPLSG-ALL-R19-blin2025
  4. 4Blinatumomab mitigates the impact of traditional adverse prognosticators among children with standard risk b-acute lymphoblastic leukemia: Updated results of the Children's oncology group (COG) Trial AALL17312025
  5. 5“upfront use of blinatumomab in adolescents and adults with Philadelphia Chromosome–Negative B-cell acute lymphoblastic leukemia: A systematic review and proportional meta-analysis”2025